Medivation Inc.

Dr. Sawyers is Chairman of Memorial Sloan-Kettering Cancer Center's Human Oncology and Pathogenesis Program (HOPP) and the first incumbent of the Marie Josee and Henry R. Kravis Chair. HOPP capitalizes on recent advances in understanding cancer cell biology and the development of molecularly targeted drugs and other rationally based interventions. It brings together physician-scientists from various clinical and scientific disciplines to conduct cutting-edge translational research across many types of cancer. Dr. Sawyers' work examines how signaling pathway abnormalities in cancer cells can be exploited as targets for new cancer drugs. The promise of this approach is best exemplified by Dr. Sawyers' key role in the clinical development of imatinib (Gleevec ), which targets the molecular cause of chronic myeloid leukemia (CML) with minimal side effects. His group subsequently deciphered the molecular basis for resistance to imatinib. Based on this insight, he led the development of a second drug called dasatinib, which is effective in CML patients whose disease fails to respond to imatinib. He has extended this approach to other diseases, including prostate cancer and glioblastoma, through laboratory-based studies that suggest new treatment strategies now undergoing clinical testing. Dr. Sawyers came to Memorial Sloan-Kettering after nearly two decades at the University of California, Los Angeles (UCLA). He received his undergraduate degree from Princeton University and his medical degree from The Johns Hopkins University. He completed a residency in internal medicine at the University of California, San Francisco, Medical Center and a clinical fellowship in hematology/oncology at the UCLA School of Medicine. He is also a Howard Hughes Medical Institute Investigator. His awards include the Doris Duke Distinguished Clinical Scientist Award, the Richard and Hinda Rosenthal Foundation Award, and the David A. Karnofsky Award.

Daniel Adams became CEO of Protein Sciences in 1995. He has previously founded and managed biopharmaceutical companies that have a combined market value of over $10 billion. He co-founded Biogen (OTC-BGEN) and served as its first President and CEO, founded and was CEO of Advanced Genetic Sciences Inc. ("AGS"), and co-founded Plant Genetic Systems in 1982. Dan holds a BA degree in Chemistry from Cornell University and a JD magna cum laude from New York University School of Law.

Over the past 25 years, Steve Gorlin has founded several highly publicized biotechnology and pharmaceutical companies, including Hycor Biomedical, Inc., Theragenics Corporation, CytRx Corporation, Medicis Pharmaceutical Corporation, EntreMed, Inc., Surgi-Vision, Inc., DARA BioSciences, Inc., and Medivation, Inc. Mr. Gorlin presently is the Chairman and CEO of DARA BioSciences, Inc. and serves on the boards of Medivation, Inc., Medeikon, Inc., Sequella Inc., NTC China, Surgi-Vision, Inc. and is Chairman of the Board of SpineMedica Corp. Mr. Gorlin served for many years on the Business Advisory Council to The Johns Hopkins School of Medicine and presently serves on the board of The Johns Hopkins Alliance for Science and Technology Development. He also founded a number of non-medical related companies, including Perma-Fix, Inc., Pretty Good Privacy, Inc., and Judicial Correction Services, Inc. He started The Touch Foundation, a nonprofit organization for the blind and was a principal financial contributor to the founding of Camp Kudzu for diabetic children. He also serves on the board of the Mercy and Sharing Foundation, providing hospital care and orphanages for over 2,000 children in Haiti. Mr. Gorlin was featured in an article on biotechnology investing in The Wall Street Journal on June 8, 1998 and in Fortune magazine on January 13, 1997.